UBS Group’s Veradermics Inc MANE Stock Holding History

UBS Group’s Portfolio MANE Stock Details MANE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$21.9M	Buy	+347,075	New	+$17.5M	﹤0.01%	2493

Other funds holding MANE

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

IAM

Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return

UBS Group's MANE Position: Q1 2026 in Review

UBS Group opened a new position in Veradermics Inc (MANE) in Q1 2026: 347,075 shares worth $21.9M. The stake represents ﹤0.01% of the portfolio and ranks #2493 among its holdings.

81 funds tracked by Wall St. Rank hold MANE as of Q1 2026.

UBS Group held 347,075 shares of Veradermics Inc worth $21.9M as of Q1 2026.
Veradermics Inc was a new UBS Group position in Q1 2026.
Veradermics Inc made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #2493 holding.
81 funds tracked by Wall St. Rank held Veradermics Inc as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.